Recruiting
Phase 3

Aleniglipron

Sponsor:

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Code:

NCT07654374

Conditions

Obesity

Overweight

Chronic Weight Management

Type2 Diabetes Mellitus

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

aleniglipron

aleniglipron

aleniglipron

Placebo

Study Details

Brief summary:

This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment.

Conditions

Obesity

Overweight

Chronic Weight Management

Type2 Diabetes Mellitus

Study ID

NCT07654374

Start date

Jul 17, 2026

Status verified date

Jun, 2026

Completion date

Nov, 2028

Anticipated

Primary completion date

Sep, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Signed Informed Consent
  • Have a BMI ≥27.0 kg/m2 at Screening
  • Have a diagnosis of T2DM according to the WHO classification or other locally applicable standards, with HbA1c ≥6.5% (≥53 mmol/mol) to ≤10% (86 mmol/mol) at Screening

Exclusion Criteria:

  • Have type 1 diabetes, history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2DM.
  • Have had 1 or more episode of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 180 days prior to Screening.
  • Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
  • Self-reported change in body weight >5 kg (11 pounds) within 3 months before Screening.
  • Have prior or planned surgical or non-surgical treatment for obesity.

Study Design

Enrollment

1100 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: aleniglipron Arm 1

Participants will receive aleniglipron administered orally.

experimental: aleniglipron Arm 2

Participants will receive aleniglipron administered orally.

experimental: aleniglipron Arm 3

Participants will receive aleniglipron administered orally.

placebo comparator: Placebo Arm 4

Participants will receive placebo administered orally.

Interventions

aleniglipron

Drug: aleniglipron administered orally

aleniglipron

Drug: aleniglipron administered orally

aleniglipron

Drug: aleniglipron administered orally

Placebo

Drug: placebo administered orally

Primary outcome measure

  • Percent change in body weight from Baseline [ Time Frame: Baseline and week 76 ]

Central Contacts and Locations

Locations

ACCOMPLISH-2 Research Site

Recruiting

Birmingham, Alabama, United States, 35242

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Chandler, Arizona, United States, 85225

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Phoenix, Arizona, United States, 85028

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Sun City West, Arizona, United States, 85375

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Tucson, Arizona, United States, 85741

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Fountain Valley, California, United States, 92708

Contacts

ACCOMPLISH-2 Research Site

Recruiting

La Jolla, California, United States, 92123

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Rolling Hills Estates, California, United States, 90274

Contacts

ACCOMPLISH-2 Research Site

Recruiting

San Diego, California, United States, 92108

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Waterbury, Connecticut, United States, 06708

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Clearwater, Florida, United States, 33756

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Fort Myers, Florida, United States, 33912

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Jacksonville, Florida, United States, 32216

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Leesburg, Florida, United States, 34748

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Ocala, Florida, United States, 34470

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Ocoee, Florida, United States, 34761

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Atlanta, Georgia, United States, 30329

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Lawrenceville, Georgia, United States, 30046

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Union City, Georgia, United States, 30291

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Woodstock, Georgia, United States, 30189

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Meridian, Idaho, United States, 83646

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Des Moines, Iowa, United States, 50314

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Wichita, Kansas, United States, 67218

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Silver Spring, Maryland, United States, 20901

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Methuen, Massachusetts, United States, 01844

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Mankato, Minnesota, United States, 56001

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Minneapolis, Minnesota, United States, 55423

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Gulfport, Mississippi, United States, 39503

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Ridgeland, Mississippi, United States, 39157

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Chesterfield, Missouri, United States, 63005

Contacts

ACCOMPLISH-2 Research Site

Recruiting

City of Saint Peters, Missouri, United States, 63303

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Hazelwood, Missouri, United States, 63042

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Springfield, Missouri, United States, 65807

Contacts

ACCOMPLISH-2 Research Site

Recruiting

St Louis, Missouri, United States, 63141

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Missoula, Montana, United States, 59804

ACCOMPLISH-2 Research Site

Recruiting

The Bronx, New York, United States, 10455

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Charlotte, North Carolina, United States, 28210

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Fayetteville, North Carolina, United States, 28304

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Morehead City, North Carolina, United States, 23730

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Winston-Salem, North Carolina, United States, 27104

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Columbus, Ohio, United States, 43213

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Moore, Oklahoma, United States, 73160

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Tulsa, Oklahoma, United States, 74133

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Yukon, Oklahoma, United States, 73099

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Portland, Oregon, United States, 97202

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Philadelphia, Pennsylvania, United States, 19152

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Greer, South Carolina, United States, 29651

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Nashville, Tennessee, United States, 37203

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Austin, Texas, United States, 78704

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Farmers Branch, Texas, United States, 75234

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Houston, Texas, United States, 77040

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Houston, Texas, United States, 77054

Contacts

ACCOMPLISH-2 Research Site

Recruiting

San Antonio, Texas, United States, 78229

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Wylie, Texas, United States, 75098

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Manassas, Virginia, United States, 20110

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Suffolk, Virginia, United States, 23435

Contacts

ACCOMPLISH-2 Research Site

Recruiting

Renton, Washington, United States, 98057

Contacts

More Information

Sponsor

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Last update posted

Oct 20, 2026

Last verified

Jun, 2026

Keywords

  • obesity
  • overweight
  • GSBR-1290
  • aleniglipron
  • chronic weight management
  • obese
  • type 2diabetes mellitus
  • small molecule
  • GLP-1
  • Structure Therapeutics

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-23. This information was provided to ClinicalTrials.gov by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics on 2026-10-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.